Gain reproducible insight into nanoparticle behaviour in solution. Detect instability, optimise formulations and accelerate nanomedicine development with Zetasizer.
Nanomedicine is transforming therapeutic delivery, enabling more targeted, controlled and effective treatments. From lipid nanoparticles and polymer carriers to inorganic nanomaterials and hybrid delivery systems, these technologies rely on precise control of particle behaviour to ensure performance, safety and manufacturability.
However, nanomedicine systems are inherently sensitive. Small changes in particle size, surface charge or aggregation behaviour can significantly impact drug delivery efficiency, biodistribution and therapeutic outcomes. These changes often begin at the nanoscale, long before they can be detected using conventional analytical techniques.
To move forward with confidence, scientists need analytical tools that provide clear, reproducible insight into nanoparticle behaviour in solution. That is why nanomedicine researchers across biotechnology companies, pharmaceutical laboratories and academic institutions rely on Malvern Panalytical's Zetasizer Advance Range, delivering nanoparticle characterisation data they can trust at every stage of development.
Works with OmniTrust: Malvern Panalytical's compliance solution for the regulated environment
Even well-designed nanomedicine systems can fail in later stages of development due to:
These risks are difficult to identify because they originate at the nanoscale, often before visible changes occur or traditional techniques can detect them.
Subtle changes in nanoparticle size, surface charge and interaction behaviour can have a significant impact on drug delivery efficiency, targeting accuracy and overall therapeutic performance. These instabilities are often missed during early development and only become apparent under real-world conditions such as scale-up, storage or biological exposure.
Zetasizer is designed to uncover these risks earlier in development.
Using highly sensitive dynamic light scattering and zeta potential analysis, Zetasizer detects even small changes in particle size distribution and surface charge. This enables scientists to identify early-stage aggregation, instability and interaction changes before they impact performance. The result is faster, more informed decision-making and reduced risk of late-stage failure.
Particle size is a critical parameter in nanomedicine. It directly influences cellular uptake, circulation time, biodistribution and drug release behaviour. Even small variations can lead to unpredictable performance in biological systems.
Zetasizer provides precise measurement of nanoparticle size distributions using dynamic light scattering. This allows researchers to monitor particle behaviour in solution throughout development and maintain tight control over formulation performance.
With Zetasizer, nanomedicine researchers can:
✔ Measure nanoparticle size with high sensitivity
✔ Monitor particle size changes during formulation optimisation
✔ Ensure consistent nanoparticle properties across experiments
This enables the design of more reliable and predictable nanomedicine delivery systems.
Nanoparticle stability is essential for maintaining consistent therapeutic performance. Unstable systems may aggregate or interact in solution, leading to reduced efficacy, inconsistent dosing and compromised delivery.
Zetasizer measures zeta potential to provide direct insight into nanoparticle surface charge and interaction behaviour. This enables scientists to predict whether particles will remain dispersed or begin to aggregate under specific formulation conditions.
With Zetasizer, scientists can:
✔ Predict colloidal stability using zeta potential measurements
✔ Evaluate how formulation variables influence nanoparticle behaviour
✔ Identify formulation conditions that minimise aggregation risk
This insight supports the development of stable nanomedicine formulations with confidence.
Aggregation can significantly alter how nanomedicines behave in biological systems. It can affect biodistribution, reduce targeting efficiency and introduce variability in drug delivery.
These changes often begin with subtle nanoscale interactions that are difficult to detect without sensitive analytical tools.
Zetasizer uses dynamic light scattering to detect early signs of aggregation by identifying small shifts in particle size distribution. This enables researchers to monitor nanoparticle behaviour throughout development and respond to instability before it becomes critical.
With Zetasizer, nanomedicine developers can:
✔ Detect early nanoparticle aggregation
✔ Monitor particle behaviour across formulation conditions
✔ Maintain consistent nanoparticle quality during development
This reduces development risk and supports more effective therapeutic outcomes.
Automated workflows powered by the Sample Assistant bring greater consistency and control to nanomedicine analysis. By standardising sample handling, measurement and data collection, the system reduces operator variability and ensures that every sample is analysed under the same conditions.
This is particularly important for nanoparticle systems, where small differences in preparation or measurement can lead to significant variation in results. Consistent workflows ensure that subtle changes in particle behaviour are detected reliably.
Designed for high-throughput environments, the Sample Assistant enables efficient screening of multiple formulations while maintaining analytical sensitivity. Dynamic light scattering and zeta potential measurements remain fully robust, while automation improves reproducibility across studies.
By embedding consistency into every stage of analysis, automated workflows support the generation of high-quality data and enable confident comparison of nanomedicine formulations.
Zetasizer combines analytical sensitivity, reproducibility and ease of use to address the complex challenges of nanomedicine development. From early research through formulation optimisation and stability testing, it provides the insight needed to understand nanoparticle behaviour in solution and reduce development risk.
With Zetasizer, you can:
✔ Measure nanoparticle size using high-sensitivity dynamic light scattering
✔ Analyse zeta potential to understand surface charge and predict stability
✔ Detect early-stage aggregation and instability
✔ Characterise nanoparticle behaviour in real formulation conditions
✔ Compare formulation variables including pH, buffers and excipients
✔ Generate highly reproducible data across experiments and users
✔ Enable high-throughput, standardised workflows with the Sample Assistant
✔ Screen multiple formulations efficiently to identify optimal conditions
✔ Reduce the risk of late-stage failure and reformulation
✔ Accelerate nanomedicine development timelines
By delivering reliable, reproducible insight into nanoparticle behaviour, Zetasizer enables scientists to make better decisions earlier, supporting the development of safe, stable and effective nanomedicine therapies with confidence.
Measure protein size and detect aggregation to optimise stability and support biologic drug development.
Characterise nanoparticle size and surface charge to optimise delivery efficiency and stability.
Verify particle size and stability to maintain product quality and regulatory compliance.
Analyse vesicle size and aggregation to support emerging therapeutic applications.
Characterize protein stability, aggregation and molecular behaviour to ensure efficacy and shelf life.
Analyse particle size and stability of antigens and delivery systems for effective vaccine performance.
Measure viral vector size and stability to ensure safe and effective gene delivery.
Understand nanoparticle size and surface properties to control drug release and targeting.
Measure size, zeta potential and concentration using DLS and NTA. Detect instability early and optimise biologics with Zetasizer and NanoSight.
The basics of Dynamic Light Scattering and electrophoretic light scattering will be discussed. I will review the Dynamic Light Scattering acronyms, i.e what is meant by NIBS and MADLS.
ZetaClass is a comprehensive webinar series on dynamic and electrophoretic light scattering where our experts walk you through the basic measuring principles, data interpretation, and tests performed to gauge data quality.
Join us as we unveil the new and expanded Zetasizer range: Zetasizer Advance. Dr Mike Kaszuba will introduce the new range and help you to pinpoint which system best fits your particle characterization requirements.
This webinar discusses some basic fundamentals of light scattering science and also common misconceptions about light scattering methods
In this webinar, you will learn about developing reliable and effective methods for dynamic light scattering (DLS) and electrophoretic light scattering (ELS) measurements using the Zetasizer Advance instrument. The presentation is geared toward users of DLS and ELS instruments who want to deepen their understanding of method development.
This webinar will explore how the Dynamic Light Scattering (DLS) technique, utilized by the Zetasizer Advance series, ensures compliance with United States Pharmacopeia (USP) guidelines, specifically USP 430.
This webinar will discuss each of the sections contained in United States Pharmacopeia (USP) 432 and what it means for users of Malvern Panalytical’s Zetasizer range of instruments who measure zeta potential in their workflow.
Join us to learn how to assess the quality of your data collected on the Zetasizer Advance instrument. Together we will go through real examples of data from particle size measurements that use Dynamic Light Scattering (DLS) and zeta potential measurements obtained with Electrophoretic Light Scattering (ELS) assessing data quality and sharing tips on how to improve confidence in the results.